Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRESS-Norway precision oncology basket trial
2023-507894-16-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib, entrectinib, selpercatinib, alpelisib, capmatinib and 25 more in cancer, sponsored by Oslo University Hospital. Primary endpoints: Number of patients treated based on molecular tumor profile, Percentage of patients treated based on molecular tumor profile and 2 more. Planned start Apr 2021; status: authorised.
02
Drugs
dabrafenib + trametinibentrectinibselpercatinibalpelisibcapmatinib
03
Conditions
cancer
Beyond the preview
Go deeper on 2023-507894-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507894-16-00.